Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Amgen's experimental drug dazodalibep hit its primary endpoint in a Phase 3 trial for Sjogren's disease, a condition that causes debilitating dryness and fatigue. The drug showed statistically significant and clinically meaningful improvement at week 48, with mostly mild side effects. Notably, Sjogren's disease currently has no approved treatments in the US.
Amgen scores a win in the race to treat Sjogren's disease
Amgen's experimental drug dazodalibep has succeeded in a late-stage clinical trial for Sjogren's disease — an autoimmune condition that attacks the body's moisture-producing glands, causing severe dryness of the eyes, mouth, and other areas, along with fatigue and chronic pain. The drug met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in disease activity at week 48.
Safety results were encouraging too, with most adverse events classified as mild to moderate and very few patients dropping out due to side effects. Amgen plans to share detailed trial data at an upcoming medical conference, with the full trial expected to wrap up in Q4 2026.
By the Numbers:
Why it matters: Sjogren's disease has long represented a significant unmet medical need with no FDA-approved therapies. With Amgen, Novartis, and Johnson & Johnson all in the race, patients may finally be on the cusp of having real treatment options.
